

Konstantinos Tziomalos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3914592/publications.pdf>

Version: 2024-02-01

355
papers

8,854
citations

50244

46
h-index

66879

78
g-index

358
all docs

358
docs citations

358
times ranked

11363
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C. <i>Gastroenterology</i> , 2023, 46, 58-66.	0.2	1
2	Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. <i>Endocrine</i> , 2022, 76, 324-330.	1.1	4
3	The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke. <i>Diseases (Basel)</i> , 2021, 11, 1078-1083.	1.0	3
4	Evaluation of Subclinical Vascular Disease in Diabetic Kidney Disease: A Tool for Personalization of Management of a High-Risk Population. <i>Journal of Personalized Medicine</i> , 2022, 12, 1139.	1.1	5
5	Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. <i>International Journal of Stroke</i> , 2021, 16, 738-750.	2.9	11
6	Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no?. <i>Annals of Gastroenterology</i> , 2021, 34, 476-486.	0.4	3
7	Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring. <i>Journal of Clinical Medicine</i> , 2021, 10, 1982.	1.0	4
8	The Role of Finerenone in the Management of Diabetic Nephropathy. <i>Diabetes Therapy</i> , 2021, 12, 1791-1797.	1.2	5
9	Heterozygous familial hypercholesterolemia: prevalence and control rates. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 175-179.	1.2	1
10	Using Serum Biomarkers for Identifying Unstable Carotid Plaque: Update of Current Evidence. <i>Current Pharmaceutical Design</i> , 2021, 27, 1899-1903.	0.9	1
11	Hepatic fibrosis is associated with higher in-hospital mortality in patients admitted with acute ischemic stroke. <i>Atherosclerosis</i> , 2021, 331, e233.	0.4	0
12	Sodium/glucose cotransporter 2 inhibitors for the treatment of type 1 diabetes: what are the latest developments?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2261-2266.	0.9	0
13	Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH. <i>Current Pharmaceutical Design</i> , 2021, 27, 2537-2544.	0.9	1
14	Prevalence of non-coronary heart disease in patients with familial hypercholesterolemia: An analysis from the HELLAS-FH. <i>Atherosclerosis</i> , 2021, 331, e185-e186.	0.4	2
15	Blood pressure variability: Prognostic implications in low-risk subjects. <i>Journal of Clinical Hypertension</i> , 2021, 23, 813-814.	1.0	1
16	Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11196.	1.8	8
17	Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?. <i>World Journal of Gastroenterology</i> , 2021, 27, 6522-6526.	1.4	4
18	LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. <i>International Journal of Cardiology</i> , 2021, 345, 119-124.	0.8	19

#	ARTICLE	IF	CITATIONS
19	The association of in vitro fertilization/intracytoplasmic sperm injection results with anxiety levels and stress biomarkers: An observational, case-control study. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021, 51, 102254.	0.6	2
20	Dilemmas and Treatment Options for Medical Conditions in the Woman's Life Span. <i>Current Pharmaceutical Design</i> , 2021, 27, 3753-3753.	0.9	0
21	The Nutrition Health Alliance (NutriHeAl) Study: A Randomized, Controlled, Nutritional Intervention Based on Mediterranean Diet in Greek Municipalities. <i>Journal of the American College of Nutrition</i> , 2020, 39, 338-344.	1.1	17
22	Secondary Hypertension: Novel Insights. <i>Current Hypertension Reviews</i> , 2020, 16, 11-11.	0.5	10
23	Sodium-Glucose Co-Transporter ² Inhibitors and Fracture Risk. <i>Diabetes Therapy</i> , 2020, 11, 7-14.	1.2	18
24	Management of obesity in adolescents with polycystic ovary syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 207-211.	0.9	14
25	Clinical characteristics of patients with familial hypercholesterolemia: Data from the HELLAS-FH registry. <i>Atherosclerosis</i> , 2020, 315, e210-e211.	0.4	0
26	Coexistence of cardiovascular risk factors in patients with familial hypercholesterolemia: Data from the HELLAS-FH registry. <i>Atherosclerosis</i> , 2020, 315, e211.	0.4	0
27	Treatment of heterozygous familial hypercholesterolemia: what does the future hold?. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1229-1234.	1.3	4
28	Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 4165-4174.	1.3	4
29	An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1799-1803.	0.9	4
30	P1270INCREASED SCLEROSTIN, BUT NOT DKK-1 PROTEIN, IS ASSOCIATED WITH ELEVATED PULSE WAVE VELOCITY IN HEMODIALYSIS SUBJECTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
31	Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry. <i>Lipids in Health and Disease</i> , 2020, 19, 114.	1.2	6
32	Oral contraceptives increase platelet microparticle levels in normal-weight women with polycystic ovary syndrome. <i>Hormones</i> , 2020, 19, 565-571.	0.9	4
33	Fixed-dose combinations of lipid-lowering and antihypertensive agents: The way forward?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 270-272.	1.0	1
34	Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management. <i>World Journal of Gastroenterology</i> , 2020, 26, 6514-6528.	1.4	25
35	Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus. <i>World Journal of Diabetes</i> , 2020, 11, 150-154.	1.3	1
36	Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. <i>World Journal of Hepatology</i> , 2020, 12, 493-505.	0.8	23

#	ARTICLE	IF	CITATIONS
37	New guidelines for the diagnosis and management of pulmonary embolism: Key changes. <i>World Journal of Cardiology</i> , 2020, 12, 161-166.	0.5	9
38	Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?. <i>World Journal of Diabetes</i> , 2020, 11, 370-373.	1.3	2
39	Increased Sclerostin, but Not Dickkopf-1 Protein, Is Associated with Elevated Pulse Wave Velocity in Hemodialysis Subjects. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 679-689.	0.9	11
40	Factors associated with delayed presentation at the emergency department in patients with acute ischemic stroke. <i>Brain Injury</i> , 2019, 33, 1257-1261.	0.6	15
41	Ambulatory arterial stiffness evaluation: A step forward in the management of hypertension. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1169-1170.	1.0	3
42	Masked hypertensives: A disguised arterial stiffness population. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1473-1480.	1.0	12
43	P5321The association of Lp(a) levels and cardiovascular disease in adult patients with familial hypercholesterolemia: analysis from the HELLAS-FH registry. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
44	A Comparison Of The Predictive Ability Of Pooled Cohort Equation, Score Equation And D:A:D Study Equation In People Living With Hiv. <i>Atherosclerosis</i> , 2019, 287, e113.	0.4	0
45	Children With Familial Hypercholesterolemia: Cardiometabolic Profile Data From The Hellas-Fh Registry. <i>Atherosclerosis</i> , 2019, 287, e210.	0.4	0
46	Impaired antioxidative activity of high-density lipoprotein is associated with more severe acute ischemic stroke. <i>Metabolism: Clinical and Experimental</i> , 2019, 98, 49-52.	1.5	10
47	Gynecology healthcare professionals towards safety procedures in operation rooms aiming to enhanced quality of medical services in Greece. <i>International Journal of Health Care Quality Assurance</i> , 2019, 32, 805-817.	0.2	1
48	Nonalcoholic Fatty Liver Disease: Current Concepts. <i>Current Pharmaceutical Design</i> , 2019, 24, 4564-4565.	0.9	0
49	The Role of Statins in the Management of Heart Failure with Preserved Ejection Fraction. <i>Current Pharmacology Reports</i> , 2019, 5, 210-213.	1.5	0
50	Effects of major adipokines and the $\delta 420 \text{ C} \rightarrow \text{G}$ resistin gene polymorphism on the long-term outcome of patients with acute ischemic stroke. <i>International Journal of Neuroscience</i> , 2019, 129, 978-985.	0.8	3
51	What special considerations must be made for the pharmacotherapeutic management of heterozygous familial hypercholesterolemia?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1175-1180.	0.9	1
52	Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review. <i>Diabetes Therapy</i> , 2019, 10, 429-435.	1.2	6
53	Greek gynecology healthcare professionals towards quality management systems. <i>International Journal of Health Care Quality Assurance</i> , 2019, 32, 164-175.	0.2	2
54	Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia – spotlight on volanesorsen. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 389-394.	1.9	10

#	ARTICLE	IF	CITATIONS
55	Apoptosis signal-regulating kinase-1 as a therapeutic target in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 189-191.	1.4	10
56	Cardiovascular risk prediction in patients with HIV infection. <i>Future Virology</i> , 2019, 14, 711-714.	0.9	0
57	Effect Of High And Low Dose Of Rosuvastatin On Fatty Liver Disease And 24-Hour Arterial Stiffness In Patients With Non-Alcoholic Fatty Liver Disease. <i>Atherosclerosis</i> , 2019, 287, e203.	0.4	0
58	P5324Children with familial hypercholesterolemia: lipid profile, treatment and evaluation of different formulas for calculating low-density lipoprotein cholesterol: an analysis from the HELLAS-FH registry. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
59	The Role of Mineralocorticoid Receptor Antagonists in the Management of Heart Failure with Preserved Ejection Fraction. <i>Current Pharmaceutical Design</i> , 2019, 24, 5525-5527.	0.9	2
60	Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 3664-3668.	1.4	8
61	Should all Hypertensive Patients be Screened for Primary Aldosteronism?. <i>Current Hypertension Reviews</i> , 2019, 15, 54-56.	0.5	0
62	Herpes Zoster and Diabetes Mellitus: A Review. <i>Diabetes Therapy</i> , 2018, 9, 545-550.	1.2	47
63	Non-Alcoholic fatty liver disease: an emerging predictor of stroke risk, severity and outcome. <i>European Journal of Neurology</i> , 2018, 25, 610-611.	1.7	6
64	Accelerated healing of a diabetic foot ulcer using autologous stromal vascular fraction suspended in platelet-rich plasma. <i>Regenerative Medicine</i> , 2018, 13, 277-281.	0.8	10
65	Fixed-dose combinations: A valuable tool to improve adherence to antihypertensive treatment. <i>Journal of Clinical Hypertension</i> , 2018, 20, 908-909.	1.0	3
66	Novel Insights in the Management of Dyslipidemia in Patients With HIV Infection. <i>Current Pharmacology Reports</i> , 2018, 4, 112-119.	1.5	1
67	Major Adipokines and the β 2C>G Resistin Gene Polymorphism as Predictors of Acute Ischemic Stroke Severity and In-Hospital Outcome. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 963-970.	0.7	8
68	Prevalence, pathogenesis and management of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome. <i>Hormones</i> , 2018, 16, 373-380.	0.9	11
69	Non-Alcoholic Fatty Liver Disease in Patients with HIV Infection. <i>AIDS Reviews</i> , 2018, 20, 171-173.	0.5	7
70	Associations between nonalcoholic fatty liver disease and ischemic stroke. <i>World Journal of Hepatology</i> , 2018, 10, 474-478.	0.8	27
71	The Role of Statins in the Management of Patients Undergoing Coronary Artery Bypass Grafting. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 102.	1.0	0
72	P736Impaired antioxidant activity of high-density lipoprotein is associated with more severe ischemic stroke. <i>European Heart Journal</i> , 2018, 39, .	1.0	0

#	ARTICLE	IF	CITATIONS
73	The challenge of gender-specific pharmacotherapy for stroke prevention and treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1849-1851.	0.9	0
74	Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Atherosclerosis</i> , 2018, 277, 308-313.	0.4	26
75	Obesity is an independent risk factor for pneumonia in patients admitted with acute ischemic stroke. <i>Atherosclerosis</i> , 2018, 275, e75.	0.4	2
76	Left ventricular hypertrophy assessed by electrocardiogram is associated with more severe stroke and with higher in-hospital mortality in patients with acute ischemic stroke. <i>Atherosclerosis</i> , 2018, 274, 206-211.	0.4	6
77	Treatment with Mannitol is Associated with Increased Risk for In-Hospital Mortality in Patients with Acute Ischemic Stroke and Cerebral Edema. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 397-403.	1.0	11
78	A Comparative Assessment of Cardiovascular Autonomic Reflex Testing and Cardiac ¹²³ I-Metaiodobenzylguanidine Imaging in Patients with Type 1 Diabetes Mellitus without Complications or Cardiovascular Risk Factors. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-7.	0.6	10
79	Obesity and Outcome of Assisted Reproduction in Patients With Polycystic Ovary Syndrome. <i>Frontiers in Endocrinology</i> , 2018, 9, 149.	1.5	18
80	Strategies to achieve low-density lipoprotein cholesterol targets in high-risk patients. <i>Current Medical Research and Opinion</i> , 2018, 34, 1713-1715.	0.9	0
81	Healthcare reform in China: challenges and opportunities. <i>Current Medical Research and Opinion</i> , 2018, 34, 821-823.	0.9	8
82	Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1277-1282.	0.8	2
83	Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease. <i>Current Pharmaceutical Design</i> , 2018, 24, 291-296.	0.9	28
84	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. <i>Current Vascular Pharmacology</i> , 2018, 16, 130-142.	0.8	54
85	Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2018, 16, 214-218.	0.8	13
86	Is There a Role for Continuous Positive Airway Pressure Treatment in the Management of Obstructive Sleep Apnea-related Hypertension?. <i>Current Hypertension Reviews</i> , 2018, 13, 89-92.	0.5	5
87	Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2018, 18, 134-138.	0.2	6
88	The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. <i>Folia Medica</i> , 2018, 60, 512-520.	0.2	3
89	Role of cenicriviroc in the management of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2018, 24, 5415-5417.	1.4	3
90	Cancer prevention in patients with human immunodeficiency virus infection. <i>World Journal of Clinical Oncology</i> , 2018, 9, 71-73.	0.9	0

#	ARTICLE	IF	CITATIONS
91	Novel insights in the prevention of perinatal transmission of hepatitis B. <i>World Journal of Hepatology</i> , 2018, 10, 795-798.	0.8	0
92	Is propofol the optimal sedative in gastrointestinal endoscopy?. <i>Acta Gastro-Enterologica Belgica</i> , 2018, 81, 520-524.	0.4	6
93	Stress hyperglycemia and acute ischemic stroke in-hospital outcome. <i>Metabolism: Clinical and Experimental</i> , 2017, 67, 99-105.	1.5	61
94	Barriers to insulin treatment in patients with type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 233-234.	0.9	4
95	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 17-32.	1.5	208
96	Vascular calcification: the role of microRNAs. <i>Biomolecular Concepts</i> , 2017, 8, 119-123.	1.0	19
97	Effect of antihypertensive treatment on the long-term outcome of patients discharged after acute ischemic stroke. <i>Clinical and Experimental Hypertension</i> , 2017, 39, 246-250.	0.5	1
98	Prevalence and geographic variation of abdominal obesity in 7- and 9-year-old children in Greece; World Health Organization Childhood Obesity Surveillance Initiative 2010. <i>BMC Public Health</i> , 2017, 17, 126.	1.2	36
99	Health benefits and consequences of the Eastern Orthodox fasting in monks of Mount Athos: a cross-sectional study. <i>European Journal of Clinical Nutrition</i> , 2017, 71, 743-749.	1.3	30
100	Blood Pressure Variability: Does it Predict the Outcome of Acute Ischemic Stroke?. <i>American Journal of Hypertension</i> , 2017, 30, 476-477.	1.0	1
101	Effects of obesity on the outcome of pneumonia. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 315-320.	1.2	5
102	Novel treatment options for the management of heterozygous familial hypercholesterolemia. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1375-1381.	1.3	12
103	Effects of major adipokines on the long-term outcome of patients with acute ischemic stroke. <i>Atherosclerosis</i> , 2017, 263, e149.	0.4	1
104	Impaired kidney function evaluated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is associated with more severe acute ischemic stroke. <i>Vascular Medicine</i> , 2017, 22, 432-434.	0.8	3
105	MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. <i>European Journal of Endocrinology</i> , 2017, 177, R145-R158.	1.9	33
106	Prognostic significance of major lipids in patients with acute ischemic stroke. <i>Metabolic Brain Disease</i> , 2017, 32, 395-400.	1.4	25
107	Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 2017, 37, 293-298.	1.5	20
108	Effects of glucose-lowering agents on ischemic stroke. <i>World Journal of Diabetes</i> , 2017, 8, 270.	1.3	4

#	ARTICLE	IF	CITATIONS
109	Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome. <i>Minerva Endocrinology</i> , 2017, 42, 122-131.	0.6	10
110	Efficacy of Administration of an Angiotensin Converting Enzyme Inhibitor for Two Years on Autonomic and Peripheral Neuropathy in Patients with Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-6.	1.0	23
111	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Hormones</i> , 2017, 16, 306-312.	0.9	9
112	Arterial stiffness correlates with the severity of hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>Atherosclerosis</i> , 2017, 263, e197.	0.4	2
113	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Hormones</i> , 2017, 13, 200-204.	0.9	2
114	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. <i>Current Pharmaceutical Design</i> , 2017, 23, 1477-1483.	0.9	6
115	The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia. <i>Current Pharmaceutical Design</i> , 2017, 23, 1495-1499.	0.9	3
116	Role of lipid-lowering agents in the management of diabetic retinopathy. <i>World Journal of Diabetes</i> , 2017, 8, 1.	1.3	15
117	Role of Metalloproteinases in the Pathogenesis of Unexpected Poor Ovarian Response with a Possible Genetic Predisposition. <i>International Journal of Infertility and Fetal Medicine</i> , 2017, 8, 5-11.	0.0	0
118	Soluble receptor for advanced glycation end products in male infertility. <i>Hippokratia</i> , 2017, 21, 19-24.	0.3	5
119	Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. <i>Hormones</i> , 2016, 15, 35-44.	0.9	17
120	Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 9039.	1.4	31
121	Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs. <i>Current Vascular Pharmacology</i> , 2016, 14, 208-210.	0.8	3
122	High-density lipoprotein: quantity or quality?. <i>Journal of Thoracic Disease</i> , 2016, 8, 2975-2977.	0.6	8
123	Acenocoumarol vs. low-dose dabigatran in real-world patients discharged after ischemic stroke. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 185-189.	0.5	1
124	Prophylactic antibiotic treatment in severe acute ischemic stroke: the Antimicrobial chemopRophylaxis for Ischemic STrokE In MaceDonlaâ€“Thrace Study (ARISTEIDIS). <i>Internal and Emergency Medicine</i> , 2016, 11, 953-958.	1.0	6
125	Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2016, 31, 1347-1353.	0.4	91
126	Obesity in patients with HIV infection: epidemiology, consequences and treatment options. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 395-402.	1.2	5

#	ARTICLE	IF	CITATIONS
127	Adherence to antihyperglycemic treatment: a work in progress. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1579-1580.	0.9	1
128	Statins for Improving Myocardial Perfusion in Patients With Nonalcoholic Fatty Liver Disease Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016, 117, 311-312.	0.7	1
129	Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. <i>Cerebrovascular Diseases</i> , 2016, 41, 226-232.	0.8	4
130	No Association Observed Between Blood Pressure Variability During the Acute Phase of Ischemic Stroke and In-Hospital Outcomes. <i>American Journal of Hypertension</i> , 2016, 29, 841-846.	1.0	23
131	The role of adipokines in ischemic stroke risk stratification. <i>International Journal of Stroke</i> , 2016, 11, 389-398.	2.9	21
132	Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 336-342.	1.0	8
133	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. <i>Hormones</i> , 2016, 15, 8-14.	0.9	7
134	Cardiovascular Risk in the Different Phenotypes of Polycystic Ovary Syndrome. <i>Current Pharmaceutical Design</i> , 2016, 22, 5547-5553.	0.9	1
135	The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease. <i>Hippokratia</i> , 2016, 20, 259-263.	0.3	6
136	Unresolved issues in lipid-lowering treatment. <i>Panminerva Medica</i> , 2016, 58, 191-5.	0.2	1
137	Effects of Different Classes of Antihypertensive Agents on the Outcome of Acute Ischemic Stroke. <i>Journal of Clinical Hypertension</i> , 2015, 17, 275-280.	1.0	9
138	Management of patients with hepatitis B in special populations. <i>World Journal of Gastroenterology</i> , 2015, 21, 1738.	1.4	39
139	Herbal medicine-related hepatotoxicity. <i>World Journal of Hepatology</i> , 2015, 7, 2189.	0.8	39
140	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , 2015, 21, 6820-6834.	1.4	120
141	Prevalence of overweight and obesity in preschool children in Thessaloniki, Greece. <i>Hormones</i> , 2015, 14, 615-22.	0.9	14
142	Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. <i>Review of Diabetic Studies</i> , 2015, 12, 110-118.	0.5	169
143	Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. <i>Hormones</i> , 2015, 14, 431-7.	0.9	17
144	Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not A. <i>Current Vascular Pharmacology</i> , 2015, 13, 696-698.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Elevated Diastolic But Not Systolic Blood Pressure Increases Mortality Risk in Hypertensive But Not Normotensive Patients With Acute Ischemic Stroke. <i>American Journal of Hypertension</i> , 2015, 28, 765-771.	1.0	19
146	Neuroleptic malignant syndrome in a patient on long-term olanzapine treatment at a stable dose: Successful treatment with dantrolene. <i>Brain Injury</i> , 2015, 29, 658-660.	0.6	8
147	Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1059-1066.	0.6	5
148	Nonalcoholic fatty liver disease and statins. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1215-1223.	1.5	68
149	Cardiovascular Risk in Middle East Populations. <i>Angiology</i> , 2015, 66, 801-802.	0.8	0
150	Clinical relevance of clopidogrel-proton pump inhibitors interaction. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2015, 6, 17.	0.6	20
151	Response to "Brachial Systolic Blood Pressure Fails to Predict Short-Term Outcome in Patients With Acute Ischemic Stroke: What About Central Systolic Pressure?" <i>American Journal of Hypertension</i> , 2015, 28, 1181-1181.	1.0	0
152	Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 463-466.	0.9	15
153	Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke. <i>Atherosclerosis</i> , 2015, 243, 65-70.	0.4	13
154	Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. <i>Current Medical Research and Opinion</i> , 2015, 31, 435-438.	0.9	4
155	Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. <i>Hormones</i> , 2015, 15, 35-44.	0.9	10
156	Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease. <i>Current Vascular Pharmacology</i> , 2015, 13, 649-657.	0.8	7
157	Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 638.	0.8	68
158	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors. <i>Hippokratia</i> , 2015, 19, 195-9.	0.3	9
159	Clinical controversies in lipid management. <i>Panminerva Medica</i> , 2015, 57, 65-70.	0.2	3
160	Editorial (Thematic Issue: Novel Data on the Pathogenesis of Atherosclerosis, Treatment Targets, and) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf Design</i> , 2014, 20, 6215-6219.	0.9	2
161	Uterine Volume and Endometrial Thickness in the Early Follicular Phase in Patients with Polycystic Ovary Syndrome. <i>Endocrine Practice</i> , 2014, 20, 540-547.	1.1	3
162	Antidiabetic treatment, stroke severity and outcome. <i>World Journal of Diabetes</i> , 2014, 5, 84.	1.3	22

#	ARTICLE	IF	CITATIONS
163	Public Awareness of Stroke Symptoms and Risk Factors and Response to Acute Stroke in Northern Greece. <i>International Journal of Stroke</i> , 2014, 9, E15-E15.	2.9	14
164	Predictive factors that influence the course of medullary thyroid carcinoma. <i>International Journal of Clinical Oncology</i> , 2014, 19, 445-451.	1.0	22
165	The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2014, 80, 432-438.	1.2	33
166	The effect of continuous positive airway pressure therapy on blood pressure and arterial stiffness in hypertensive patients with obstructive sleep apnea. <i>Sleep and Breathing</i> , 2014, 18, 635-640.	0.9	24
167	Sex-specific Differences in Cardiovascular Risk Factors and Blood Pressure Control in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2014, 16, 309-312.	1.0	16
168	Increased augmentation index is paradoxically associated with lower in-hospital mortality in patients with acute ischemic stroke. <i>Atherosclerosis</i> , 2014, 236, 150-153.	0.4	13
169	Combined Chelation Therapy with Deferoxamine and Deferiprone in β^2 -Thalassemia Major: Compliance and Opinions of Young Thalassaemic Patients. <i>Hemoglobin</i> , 2014, 38, 111-114.	0.4	10
170	Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 74-82.	2.3	75
171	Are antibodies against PCSK9 the statins of the 21st century?. <i>Clinical Lipidology</i> , 2014, 9, 141-144.	0.4	0
172	Predictive value of the ankle brachial index in patients with acute ischemic stroke. <i>Vasa - European Journal of Vascular Medicine</i> , 2014, 43, 55-61.	0.6	11
173	Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2014, 20, 6106-6113.	0.9	6
174	Alcohol and the Cardiovascular System: A Double-Edged Sword. <i>Current Pharmaceutical Design</i> , 2014, 20, 6276-6288.	0.9	27
175	Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all. <i>Current Pharmaceutical Design</i> , 2014, 20, 6350-6357.	0.9	9
176	Effects of Lipid-Lowering Agents on Inflammation, Haemostasis and Blood Pressure. <i>Current Pharmaceutical Design</i> , 2014, 20, 6306-6313.	0.9	9
177	Type 2 diabetes is associated with a worse functional outcome of ischemic stroke. <i>World Journal of Diabetes</i> , 2014, 5, 939.	1.3	40
178	Lipid-lowering agents in the management of nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2014, 6, 738.	0.8	15
179	Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. <i>Endocrine</i> , 2013, 44, 583-590.	1.1	72
180	Impaired Fasting Glucose in Hypertensive Patients: Prevalence and Cross-Sectional Analysis of Associations with Cardiovascular Disease. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 475-480.	2.4	3

#	ARTICLE	IF	CITATIONS
181	Metabolic syndrome in patients with the polycystic ovary syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 559-568.	1.2	2
182	Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2013, 29, 250-253.	0.7	26
183	The prognostic significance of nonalcoholic fatty liver disease in patients with acute ischemic stroke. <i>European Journal of Internal Medicine</i> , 2013, 24, e48.	1.0	0
184	Prevalence of metabolic syndrome in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2013, 78, 586-592.	1.2	54
185	The Increase in Thyroid Cancer Incidence is not only due to Papillary Microcarcinomas: a 40-year Study in 1 778 Patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2013, 121, 397-401.	0.6	18
186	Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome. <i>Human Reproduction</i> , 2013, 28, 785-793.	0.4	18
187	The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2013, 168, 871-877.	1.9	17
188	Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2013, 168, 145-152.	1.9	31
189	Effect of Prior Treatment with Different Statins on Stroke Severity and Functional Outcome at Discharge in Patients with Acute Ischemic Stroke. <i>International Journal of Stroke</i> , 2013, 8, E49-E49.	2.9	6
190	Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2013, 29, 926-930.	0.7	16
191	Prevalence of resistant hypertension in 1810 patients followed up in a specialized outpatient clinic and its association with the metabolic syndrome. <i>Blood Pressure</i> , 2013, 22, 307-311.	0.7	5
192	Bariatric surgery as a treatment option in patients with type 2 diabetes mellitus. <i>World Journal of Diabetes</i> , 2013, 4, 14.	1.3	8
193	Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome. <i>Hormones</i> , 2013, 12, 559-566.	0.9	13
194	Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. <i>Archives of Medical Science</i> , 2013, 3, 418-426.	0.4	40
195	The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require reconsideration. <i>Hormones</i> , 2013, 12, 192-200.	0.9	12
196	Colesevelam: A New and Improved Bile Acid Sequestrant?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3115-3123.	0.9	17
197	Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension. <i>Current Pharmaceutical Design</i> , 2013, 19, 3766-3772.	0.9	8
198	The Impact of Smoking on Cardiovascular Outcomes and Comorbidities in Statin-treated Patients with Coronary Artery Disease: A Post hoc Analysis of the GREACE Study. <i>Current Vascular Pharmacology</i> , 2013, 11, 779-784.	0.8	19

#	ARTICLE	IF	CITATIONS
199	Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome. <i>World Journal of Hepatology</i> , 2013, 5, 621.	0.8	26
200	Inhibition of apoptosis in the management of nonalcoholic fatty liver disease. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2013, 4, 4.	0.6	10
201	Calcitonin stimulation tests for the early diagnosis and follow-up of patients with C cell disease: a descriptive analysis. <i>Hippokratia</i> , 2013, 17, 246-51.	0.3	3
202	Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome. <i>Angiology</i> , 2012, 63, 358-366.	0.8	27
203	Adipokines, Insulin Resistance and Hyperandrogenemia in Obese Patients with Polycystic Ovary Syndrome: Cross-Sectional Correlations and the Effects of Weight Loss. <i>Obesity Facts</i> , 2012, 5, 495-504.	1.6	26
204	Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. <i>Human Reproduction</i> , 2012, 27, 541-549.	0.4	117
205	Lipid Lowering Agents and the Endothelium: An Update after 4 Years. <i>Current Vascular Pharmacology</i> , 2012, 10, 33-41.	0.8	18
206	Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options. <i>Current Vascular Pharmacology</i> , 2012, 10, 162-172.	0.8	42
207	P4.62 PROGNOSTIC VALUE OF ARTERIAL STIFFNESS INDICES IN PATIENTS WITH ACUTE ISCHEMIC STROKE. <i>Artery Research</i> , 2012, 6, 200.	0.3	0
208	Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2012, 97, 494-500.	0.5	37
209	Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2012, 28, 20-24.	0.7	19
210	Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. <i>World Journal of Hepatology</i> , 2012, 4, 327.	0.8	84
211	Plasma Von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome. <i>Hormones</i> , 2012, 11, 77-85.	0.9	7
212	Management of type 2 diabetes mellitus in youth. <i>World Journal of Diabetes</i> , 2012, 3, 182.	1.3	1
213	Cardiovascular diseases in pregnancy. <i>American Journal of Cardiovascular Disease</i> , 2012, 2, 96-101.	0.5	0
214	Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. <i>Current Medical Research and Opinion</i> , 2011, 27, 1659-1668.	0.9	47
215	Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. <i>Annals of Medicine</i> , 2011, 43, 167-171.	1.5	39
216	Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 213-221.	1.1	66

#	ARTICLE	IF	CITATIONS
217	Raised liver enzymes in patients taking statins – Authors' reply. <i>Lancet</i> , The, 2011, 377, 1075-1076.	6.3	1
218	Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 85-89.	0.6	11
219	Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 24-34.	0.6	55
220	State of the art papers Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. <i>Archives of Medical Science</i> , 2011, 6, 1067-1075.	0.4	9
221	Improving the Implementation of Current Guidelines for the Management of Major Coronary Heart Disease Risk Factors by Multifactorial Intervention. The IMPERATIVE renal analysis. <i>Archives of Medical Science</i> , 2011, 6, 984-992.	0.4	46
222	Malnutrition in Patients with Acute Stroke. <i>Journal of Nutrition and Metabolism</i> , 2011, 2011, 1-7.	0.7	65
223	Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. <i>Archives of Medical Science</i> , 2011, 5, 796-805.	0.4	72
224	Atherosclerotic Renal Artery Stenosis: An Update on Diagnosis and Management. <i>Current Vascular Pharmacology</i> , 2011, 9, 465-470.	0.8	1
225	Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women. <i>Current Vascular Pharmacology</i> , 2011, 9, 647-657.	0.8	44
226	Cardiovascular benefits of bariatric surgery in morbidly obese patients. <i>Obesity Reviews</i> , 2011, 12, 515-524.	3.1	72
227	Can Capsule Endoscopy Be Used as a Diagnostic Tool in the Evaluation of Nonbleeding Indications in Daily Clinical Practice? A Prospective Study. <i>Medical Principles and Practice</i> , 2011, 20, 362-367.	1.1	11
228	The Phenotypes of Polycystic Ovary Syndrome Defined by the 1990 Diagnostic Criteria Are Associated with Higher Serum Vaspin Levels than the Phenotypes Introduced by the 2003 Criteria. <i>Obesity Facts</i> , 2011, 4, 145-150.	1.6	16
229	Circulating platelet-derived microparticles are elevated in women with polycystic ovary syndrome diagnosed with the 1990 criteria and correlate with serum testosterone levels. <i>European Journal of Endocrinology</i> , 2011, 165, 63-68.	1.9	25
230	Editorial: Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 226-230.	0.6	6
231	Prevalence of overweight and abdominal obesity in Greek children 6-12 years old: Results from the National Epidemiological Survey. <i>Hippokratia</i> , 2011, 15, 48-53.	0.3	20
232	The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis. <i>Current Vascular Pharmacology</i> , 2010, 8, 792-803.	0.8	13
233	Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?. <i>Current Drug Targets</i> , 2010, 11, 122-135.	1.0	100
234	The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. <i>Current Opinion in Cardiology</i> , 2010, 25, 394-398.	0.8	27

#	ARTICLE	IF	CITATIONS
235	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. <i>Current Opinion in Cardiology</i> , 2010, 25, 406-410.	0.8	23
236	Liver iron content determination by magnetic resonance imaging. <i>World Journal of Gastroenterology</i> , 2010, 16, 1587.	1.4	42
237	Brain natriuretic peptide and the athlete's heart: a pilot study. <i>International Journal of Clinical Practice</i> , 2010, 64, 511-517.	0.8	15
238	Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg ⁺ chronic hepatitis B patients: A 4-year study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 54-60.	1.4	34
239	Coagulation and inflammation biomarkers may help predict the severity of community-acquired pneumonia. <i>Respirology</i> , 2010, 15, 796-803.	1.3	31
240	Editorial [Concurrent Blood Pressure, Glycemic and Lipid Control for the Prevention of Vascular Complications of Type II Diabetes Mellitus: A Long Overdue Objective?]. <i>Current Vascular Pharmacology</i> , 2010, 8, 1-4.	0.8	3
241	Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 723-730.	0.9	22
242	Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. <i>Current Medical Research and Opinion</i> , 2010, 26, 713-719.	0.9	93
243	Statin-fibrate combination for mixed dyslipidaemia: a limited option?. <i>Current Medical Research and Opinion</i> , 2010, 26, 2137-2140.	0.9	7
244	Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2604-2609.	3.3	95
245	Lipid-lowering agents and new onset diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1965-1970.	0.9	16
246	Effects of Lifestyle Measures, Antiobesity Agents, and Bariatric Surgery on Serological Markers of Inflammation in Obese Patients. <i>Mediators of Inflammation</i> , 2010, 2010, 1-14.	1.4	24
247	Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients. <i>Neurological Research</i> , 2010, 32, 326-331.	0.6	26
248	Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. <i>Current Medical Research and Opinion</i> , 2010, 26, 839-842.	0.9	22
249	To switch (statins) or not to switch? That is the question. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2943-2946.	0.9	7
250	Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 140-146.	1.1	139
251	Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: Incidence and correlation with disease severity and survival. <i>Hepatology Research</i> , 2010, 40, 161-170.	1.8	32
252	Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: Beneficial or detrimental?. <i>Atherosclerosis</i> , 2010, 211, 9-14.	0.4	45

#	ARTICLE	IF	CITATIONS
253	Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. <i>Lancet, The</i> , 2010, 376, 1916-1922.	6.3	594
254	Atorvastatin: safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 667-674.	1.0	38
255	Management of Statin-Intolerant High-Risk Patients. <i>Current Vascular Pharmacology</i> , 2010, 8, 632-637.	0.8	14
256	Endocrine Hypertension: Diagnosis and Management of a Complex Clinical Entity. <i>Current Vascular Pharmacology</i> , 2010, 8, 646-660.	0.8	17
257	Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B. <i>World Journal of Hepatology</i> , 2010, 2, 91.	0.8	7
258	The use of sibutramine in the management of obesity and related disorders: An update. <i>Vascular Health and Risk Management</i> , 2009, 5, 441.	1.0	57
259	Treatment of congenital fibrinogen deficiency: overview and recent findings. <i>Vascular Health and Risk Management</i> , 2009, 5, 843.	1.0	45
260	Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 57-68.	0.6	5
261	Adrenal incidentaloma: a diagnostic challenge. <i>Hormones</i> , 2009, 8, 163-184.	0.9	68
262	JUPITER: major implications for vascular risk assessment. <i>Current Medical Research and Opinion</i> , 2009, 25, 133-137.	0.9	8
263	Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?. <i>Angiology</i> , 2009, 60, 74-81.	0.8	10
264	Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2009, 5, 16-17.	2.9	12
265	Dyslipidemia as a Risk Factor for Ischemic Stroke. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1291-1297.	1.0	69
266	Anti-Inflammatory Effects of Fibrates: An Overview. <i>Current Medicinal Chemistry</i> , 2009, 16, 676-684.	1.2	26
267	Diabetes mellitus and cerebrovascular disease: which are the actual data?. <i>Journal of Diabetes and Its Complications</i> , 2009, 23, 283-296.	1.2	23
268	Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?. <i>Osteoporosis International</i> , 2009, 20, 197-207.	1.3	146
269	Atherosclerotic Renal Artery Stenosis: Medical Therapy Alone or in Combination with Revascularization?. <i>Angiology</i> , 2009, 60, 397-402.	0.8	5
270	Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. <i>International Journal of Cardiology</i> , 2009, 134, 322-329.	0.8	26

#	ARTICLE	IF	CITATIONS
271	The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2692-2701.	1.8	518
272	Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. <i>Current Medical Research and Opinion</i> , 2009, 25, 1931-1940.	0.9	11
273	Lipoprotein a: where are we now?. <i>Current Opinion in Cardiology</i> , 2009, 24, 351-357.	0.8	52
274	Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 183-189.	0.8	28
275	The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women. <i>Current Pharmaceutical Design</i> , 2009, 15, 1054-1062.	0.9	21
276	Pleiotropic Effects of Statins - Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2009, 15, 479-489.	0.9	144
277	Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies. <i>Current Drug Targets</i> , 2009, 10, 320-327.	1.0	27
278	Editorial: [Statins and Cardiovascular Events in Patients with End-Stage Renal Disease on Hemodialysis. The AURORA Results Suggest the Need for Earlier Intervention]. <i>Current Vascular Pharmacology</i> , 2009, 7, 264-266.	0.8	12
279	Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 26-34.	0.6	16
280	Combination treatment in HBeAg-negative chronic hepatitis B. <i>World Journal of Hepatology</i> , 2009, 1, 43.	0.8	3
281	Buflomedil: potential new indications for an old agent. <i>International Angiology</i> , 2009, 28, 170-4.	0.4	3
282	Omega-3 fatty acids: How can they be used in secondary prevention?. <i>Current Atherosclerosis Reports</i> , 2008, 10, 510-517.	2.0	15
283	Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. <i>Acta Diabetologica</i> , 2008, 45, 23-30.	1.2	24
284	Neuropeptide Y and alpha-melanocyte-stimulating hormone: interaction in obesity and possible role in the development of hypertension. <i>International Journal of Clinical Practice</i> , 2008, 62, 1432-1440.	0.8	46
285	Epidemiological Survey for the Prevalence of Overweight and Abdominal Obesity in Greek Adolescents. <i>Obesity</i> , 2008, 16, 1718-1722.	1.5	66
286	Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients. <i>American Journal of Cardiology</i> , 2008, 101, 483-485.	0.7	68
287	Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 809-820.	1.5	12
288	Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 969-972.	1.9	13

#	ARTICLE	IF	CITATIONS
289	Vascular risk factors in South Asians. <i>International Journal of Cardiology</i> , 2008, 128, 5-16.	0.8	46
290	Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1437-1440.	0.9	6
291	Spirolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 509-515.	0.9	115
292	Nitric Oxide and Cardiobiology—Methods for Intact Hearts and Isolated Myocytes. <i>Methods in Enzymology</i> , 2008, 441, 369-392.	0.4	10
293	CORONA, Statins, and Heart Failure: Who Lost the Crown?. <i>Angiology</i> , 2008, 59, 5-8.	0.8	7
294	Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. <i>Endocrine-Related Cancer</i> , 2008, 15, 693-700.	1.6	24
295	Statin discontinuation: an underestimated risk?. <i>Current Medical Research and Opinion</i> , 2008, 24, 3059-3062.	0.9	44
296	Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 445-449.	1.9	8
297	High Density Lipoprotein Cholesterol and Statin Trials. <i>Current Medicinal Chemistry</i> , 2008, 15, 2265-2270.	1.2	16
298	Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. <i>Current Medical Research and Opinion</i> , 2008, 24, 1593-1599.	0.9	22
299	Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1777-1779.	1.9	5
300	Editorial [Has the Time Come for a New Definition of Microalbuminuria?]. <i>Current Vascular Pharmacology</i> , 2008, 6, 81-83.	0.8	6
301	Statins for the Prevention of First or Recurrent Stroke. <i>Current Vascular Pharmacology</i> , 2008, 6, 124-133.	0.8	19
302	Atherogenesis in Renal Patients: A Model of Vascular Disease?. <i>Current Vascular Pharmacology</i> , 2008, 6, 93-107.	0.8	36
303	Can We Move Forward After ADVANCE?. <i>Vascular Disease Prevention</i> , 2008, 5, 72-74.	0.2	0
304	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2267-2277.	0.9	11
305	Atenolol: Differences in Mode of Action Compared with other Antihypertensives. An Opportunity to Identify Features that Influence Outcome?. <i>Current Pharmaceutical Design</i> , 2007, 13, 229-239.	0.9	11
306	Fish Oils and Vascular Disease Prevention: An Update. <i>Current Medicinal Chemistry</i> , 2007, 14, 2622-2628.	1.2	34

#	ARTICLE	IF	CITATIONS
307	Association of Drinking Pattern and Alcohol Beverage Type With the Prevalence of Metabolic Syndrome, Diabetes, Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Mediterranean Cohort. <i>Angiology</i> , 2007, 58, 689-697.	0.8	133
308	Endothelial function, arterial stiffness and lipid lowering drugs. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1143-1160.	1.5	39
309	Seasonality of month of birth of patients with Graves' and Hashimoto's diseases differ from that in the general population. <i>European Journal of Endocrinology</i> , 2007, 156, 631-636.	1.9	45
310	Short-term Administration of Orlistat Reduced Daytime Triglyceridemia in Obese Women With the Metabolic Syndrome. <i>Angiology</i> , 2007, 58, 26-33.	0.8	12
311	Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels. <i>Current Drug Targets</i> , 2007, 8, 483-488.	1.0	27
312	Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 529-535.	0.9	68
313	Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke. <i>Circulation Journal</i> , 2007, 71, 1120-1127.	0.7	119
314	Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1582-1588.	1.4	14
315	Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy. <i>European Journal of Haematology</i> , 2007, 78, 48-51.	1.1	18
316	Atorvastatin Decreases Triacylglycerol-Associated Risk of Vascular Events in Coronary Heart Disease Patients. <i>Lipids</i> , 2007, 42, 999-1009.	0.7	35
317	Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. <i>Open Cardiovascular Medicine Journal</i> , 2007, 1, 8-14.	0.6	27
318	Persistent effect of zoledronic acid in Paget's disease. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, 464-6.	0.4	2
319	Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. <i>Current Medical Research and Opinion</i> , 2006, 22, 873-883.	0.9	238
320	Skin Involvement in Hodgkin's Disease. <i>Cancer Investigation</i> , 2006, 24, 401-403.	0.6	11
321	Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review. <i>International Journal of Nanomedicine</i> , 2006, 1, 129-147.	3.3	46
322	Reversible dilated hypocalcaemic cardiomyopathy in a patient with primary hypoparathyroidism. <i>Clinical Endocrinology</i> , 2006, 64, 717-718.	1.2	17
323	Management of acute bleeding in a patient with congenital afibrinogenaemia. <i>Haemophilia</i> , 2006, 12, 676-678.	1.0	14
324	DRY COUGH AS FIRST MANIFESTATION OF GIANT-CELL ARTERITIS. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1957-1958.	1.3	11

#	ARTICLE	IF	CITATIONS
325	Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. <i>Annals of Hematology</i> , 2006, 86, 23-30.	0.8	32
326	Ductal plate malformation and congenital hepatic fibrosis Clinical and histological findings in four patients. <i>Hepatology Research</i> , 2006, 35, 147-150.	1.8	12
327	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 118-127.	0.4	158
328	Pegylated IFN- α 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2006, 12, 2417.	1.4	12
329	A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis. <i>World Journal of Gastroenterology</i> , 2006, 12, 818.	1.4	3
330	Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. <i>Clinical Transplantation</i> , 2005, 19, 321-326.	0.8	17
331	Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 531-537.	1.9	24
332	Mitral valve reconstruction in a compound heterozygote for sickle cell anemia and hemoglobin Lepore. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 130, 932-933.	0.4	6
333	Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy "A prospective case series. <i>American Journal of Hematology</i> , 2005, 80, 197-203.	2.0	52
334	Hereditary spherocytosis uncovered in adulthood due to concomitant lead poisoning. <i>Annals of Hematology</i> , 2005, 84, 131-132.	0.8	0
335	Protein-losing enteropathy as the principal manifestation of constrictive pericarditis. <i>Journal of General Internal Medicine</i> , 2005, 20, C5-C7.	1.3	8
336	The Unilateral Measurement of Blood Pressure May Mask the Diagnosis or Delay the Effective Treatment of Hypertension. <i>Angiology</i> , 2005, 56, 565-569.	0.8	22
337	Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia After Treatment with Imatinib Mesylate. <i>Oncologist</i> , 2005, 10, 457-458.	1.9	28
338	Uncommon manifestation of bleomycin-induced pulmonary toxicity in a patient with Hodgkin's disease. <i>Annals of Oncology</i> , 2005, 16, 514-515.	0.6	3
339	Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 913-915.	0.2	8
340	Targeting vascular risk in patients with metabolic syndrome but without diabetes. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1065-1074.	1.5	66
341	Multifocal mucosa-associated lymphoid tissue lymphoma presenting as lower-GI bleeding. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 465-467.	0.5	0
342	Prevalence and severity of liver disease in patients with b thalassaemia major. A single-institution fifteen-year experience. <i>Haematologica</i> , 2005, 90, 1136-8.	1.7	15

#	ARTICLE	IF	CITATIONS
343	Cardiac Toxicity During Rituximab Administration. <i>Leukemia and Lymphoma</i> , 2004, 45, 203-204.	0.6	18
344	Lack of an Association between Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Ischaemic Stroke. <i>European Neurology</i> , 2004, 51, 148-152.	0.6	21
345	Lack of an association between angiotensin converting enzyme gene polymorphism and peripheral arterial occlusive disease. <i>Vascular Medicine</i> , 2004, 9, 189-192.	0.8	6
346	Paralysis as first manifestation of primary aldosteronism. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2418-2419.	0.4	4
347	Focal nodular hyperplasia of the liver in a patient with primary aldosteronism. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 480-481.	1.4	1
348	Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid. <i>British Journal of Haematology</i> , 2004, 125, 91-92.	1.2	26
349	Endocrine effects of tobacco smoking. <i>Clinical Endocrinology</i> , 2004, 61, 664-674.	1.2	60
350	Endoscopic variceal ligation for portal hypertension due to myelofibrosis with myeloid metaplasia. <i>European Journal of Haematology</i> , 2004, 72, 379-380.	1.1	2
351	Gardnerâ€Diamond Syndrome. <i>Journal of Dermatology</i> , 2004, 31, 587-588.	0.6	1
352	Treatment of idiopathic retroperitoneal fibrosis with combined administration of corticosteroids and tamoxifen. <i>Clinical Nephrology</i> , 2004, 62, 74-76.	0.4	4
353	Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. <i>Haematologica</i> , 2004, 89, 245-6.	1.7	47
354	Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2003, 123, 958-958.	1.2	10
355	Elevated Levels of Serum Vascular Endothelial Growth Factor in Patients with Polycythaemia vera. <i>Acta Haematologica</i> , 2003, 110, 16-19.	0.7	7